In a Phase 3 trial of 500 people, patients with advanced pancreatic cancer who had already received treatment lived an average of 13.2 months while taking daraxonrasib. Patients receiving standard chemotherapy lived an average of 6.7 months. That means the drug nearly doubled average survival, while also causing fewer side effects.
The drug works by blocking proteins made by RAS genes, especially KRAS. More than 90% of pancreatic cancers involve KRAS, but the gene has been extremely difficult to target with drugs.
The results received a standing ovation when they were presented at the 2026 meeting of the American Society of Clinical Oncology. One oncologist called the results "unprecedented," pointing out that no drug had previously shown a survival benefit close to a year in a Phase 3 pancreatic cancer trial.
Daraxonrasib has not yet received full FDA approval. However, the FDA has authorized an expanded access program that allows eligible patients to receive the drug. It has also received several special designations designed to speed up its path toward approval.
Pancreatic cancer remains one of the hardest cancers to treat. It can grow quickly, resist treatment, and often causes few symptoms until it is already advanced. A drug that can significantly extend survival could represent an important step forward.
BioNTech developed this vaccine with Genentech. It is made using genetic information from a patient's own tumor after surgery. The vaccine is then combined with chemotherapy to teach the immune system to recognize and attack cancer cells that may remain in the body.
In an early clinical trial led by Memorial Sloan Kettering Cancer Center, nearly all of the patients who responded to the vaccine were still alive six years later. That is a striking result for pancreatic cancer, where five-year survival has historically been very low. A related vaccine is also being developed. It uses shared cancer targets and is designed to attack KRAS mutations directly.
Pancreatic cancer has been difficult to treat with immunotherapy because these tumors often do not create a strong immune response. A personalized vaccine may help solve that problem by giving the immune system a specific target to attack.
In August 2026, the vaccine became the first personalized mRNA cancer vaccine to succeed in a large, late-stage Phase 3 trial.
The vaccine was given along with Keytruda, an existing immunotherapy drug. The combination significantly reduced the risk of cancer returning or spreading in patients with high-risk melanoma that had already been surgically removed. Earlier research had shown that the combination could cut the risk of cancer returning or causing death by about half compared with Keytruda alone. The treatment works by studying a patient's tumor to find its unique mutations. The mRNA vaccine then gives the immune system a personalized list of targets to look for.
Because this is the first major Phase 3 success for a personalized mRNA cancer vaccine, companies are already working with regulators. Doctors interviewed about the results expect the treatment could be approved and available as soon as early 2027. Researchers are also testing the same vaccine approach against bladder, kidney, lung, stomach, and pancreatic cancers. The melanoma results could be an early sign of a much larger wave of personalized cancer vaccines.
Casgevy was the first CRISPR-based treatment ever approved. It edits a patient's own blood stem cells to treat sickle cell disease and beta thalassemia. The treatment is now available in 39 countries and has recently been expanded to children as young as 2 years old. Another CRISPR-based treatment, EDIT-101, has also been approved for a rare inherited form of blindness.
Other CRISPR treatments are being tested in late-stage clinical trials for conditions including hereditary angioedema, familial high cholesterol, Huntington's disease, and Duchenne muscular dystrophy. Until recently, many of these genetic diseases could not be treated at their source. Casgevy is designed to address the underlying genetic problem instead of simply controlling symptoms.
The treatment is given as a one-time procedure rather than as a lifelong therapy. A patient's cells are removed from the body, genetically edited, and then returned to the patient. The biggest challenges now include cost and access. A treatment can cost more than $2 million, and it requires specialized medical centers to perform the procedure. That makes 2026 an important test of whether gene editing can expand beyond a small number of highly specialized facilities.
In a small but closely watched trial, 10 of 12 patients who received a single infusion of zimislecel no longer needed insulin after one year. All 12 reached their target blood sugar levels, and none had a severe low-blood-sugar episode after the first 90 days.
The treatment uses lab-grown, mature insulin-producing cells. These cells are delivered directly into the liver through an infusion. The goal is to replace the cells that are destroyed by the immune system in people with type 1 diabetes. Vertex Pharmaceuticals, which developed the treatment, expects to submit it for FDA approval sometime in 2026. The treatment is not considered a true cure because patients still need drugs that suppress the immune system. These medications are needed to prevent the body from rejecting the new cells, and immune suppression has caused some serious side effects in the larger trial group.
Still, for people who currently need insulin injections and regular blood sugar monitoring for life, the treatment could be an important step toward a functional cure.
In one of the first small trials of this approach, five people with severe lupus who had not responded to other treatments went into full remission within three months of receiving CAR-T therapy. They were also able to stop taking their other lupus medications.
The treatment takes a patient's own T-cells and genetically changes them. The modified cells are designed to find and destroy the antibody-producing cells that drive lupus. The modified cells are then put back into the patient's body. The antibody-producing B cells return several months later. However, researchers found that the lupus symptoms did not return with them.
Researchers describe the approach as more of an immune system "reset" than simply suppressing the immune system. Larger trials backed by pharmaceutical companies, including Bristol Myers Squibb and Cabaletta Bio, have reported similar results. Researchers are also studying whether the same approach could work for other autoimmune diseases.
If larger studies confirm these results, CAR-T therapy could become an important way to change the course of lupus instead of simply managing its flare-ups.
Doctors can now use a simple blood test to help diagnose Alzheimer's instead of relying only on expensive PET scans or an invasive spinal tap. The test looks for a protein called p-tau217. This protein is linked to the buildup of amyloid plaques associated with Alzheimer's disease. A second version of the test that can be used more easily in primary-care settings was cleared in late 2025.
This comes as researchers have also developed the first drugs shown to slow the progression of early Alzheimer's disease rather than simply treating its symptoms. Blood testing could eventually help doctors identify people at risk of developing Alzheimer's more than a decade before symptoms appear. That could open the door to earlier treatment and possibly prevention.
For patients and families, a faster and less expensive way to identify the disease could mean earlier access to available treatments and less time waiting for answers.
The FDA has approved the first formal clinical trials involving pig kidneys transplanted into living human patients. The trials are being conducted separately by United Therapeutics and eGenesis. This moves the field beyond the small number of one-time, compassionate-use transplants performed in recent years.
The pigs used in these trials have been genetically modified to make their organs less likely to be rejected by the human immune system. The early trial patients have end-stage kidney disease and are not eligible for a traditional transplant. For these patients, there may be few other options.
The development could have a major impact because more than 100,000 people are currently on transplant waiting lists in the United States. About 17 people die each day while waiting for a donor organ. If these trials are successful, pig organs could eventually help solve one of medicine's biggest problems: the shortage of organs available for transplant.
A 2026 study from the University of Pennsylvania, presented at ASCO, found that women taking GLP-1 medications were about 30% less likely to develop breast cancer than women who were not taking the drugs.
This is the latest finding involving medications that were originally developed to treat type 2 diabetes. GLP-1 drugs have already been linked to lower risks of heart attacks, strokes, kidney disease progression, and sleep apnea.
However, researchers caution that the breast cancer finding came from an observational study. That means it found a strong connection between the two factors, but it does not prove that GLP-1 drugs prevent breast cancer. Researchers are now planning a clinical trial to find out whether the connection is real and how much of the effect may be related to the weight loss caused by these medications.
Even with that uncertainty, researchers are interested in how one class of drugs developed for one condition may affect several others.
ADCs combine a powerful chemotherapy drug with an antibody designed to find specific markers on cancer cells. The goal is to deliver the drug directly to the tumor while limiting the damage to healthy cells.
Recent approvals, including zongertinib for a specific type of HER2-mutant lung cancer, show how cancer treatment is becoming more targeted. Instead of using the same treatment for every patient with the same type of cancer, doctors can increasingly look at the specific characteristics of a tumor and choose treatments based on those findings.
Oncologists say the future of cancer treatment may not depend on finding one miracle drug. Instead, it may involve combining several targeted treatments that are designed for each patient's specific cancer. For patients, the goal is treatment that works more effectively while causing fewer of the harsh, whole-body side effects associated with traditional chemotherapy.
A growing number of AI tools are now being used to help with breast cancer screening and to detect strokes and heart problems. More widespread use is expected during 2026.
These tools are designed to work alongside doctors and radiologists rather than replace them. They can flag possible problems, identify things that might otherwise be missed, or help doctors spot serious conditions faster. That could give doctors more time to focus on their patients instead of spending as much time reviewing scans.
AI is also being used behind the scenes to speed up medical research. For example, it can help scientists design gene-editing experiments and plan safer, more precise genetic changes. The basic promise is straightforward: faster and more consistent detection of disease. For conditions such as cancer and stroke, finding a problem earlier can make a major difference in a patient's outcome.
Telemedicine has grown beyond simple video calls with doctors. Virtual hospitals are becoming centers that can provide a much wider range of medical care remotely. Some services can be delivered directly to patients in their homes. Others connect smaller medical facilities with specialists who may be located hundreds or thousands of miles away.
Saudi Arabia's SEHA Virtual Hospital already connects 130 healthcare facilities and has the capacity to treat 400,000 patients each year. The United Kingdom's National Health Service has also announced plans to create its own version. For people who live in rural or underserved areas, this model could provide access to specialists who were previously difficult to reach. It could also help patients who have trouble traveling to medical centers. As populations age and the need for specialists grows, virtual healthcare could become an increasingly important part of the medical system.
In a Phase 3 trial presented at ASCO 2026, ivonescimab performed better than a standard immunotherapy treatment in a direct comparison involving patients with squamous non-small-cell lung cancer.
Ivonescimab is designed to target two different cancer-related targets at the same time. Beating an existing standard treatment in a head-to-head trial is an important result in cancer research. It also reflects a larger trend toward drugs that attack cancer in more than one way. Lung cancer remains the leading cause of cancer death around the world. As a result, improvements in the first treatment given to patients could have a significant impact.
The OPTIMA trial, presented at ASCO 2026, found that about two-thirds of high-risk breast cancer patients could safely avoid chemotherapy when doctors used the Prosigna genomic test to help guide treatment decisions.
The test looks at the genetic activity inside a tumor. It can help predict how likely a tumor is to respond to treatment and whether chemotherapy is likely to be needed. The test is already commercially available. This is an example of a breakthrough that does not involve a new drug. Instead, it gives doctors a better way to decide which patients actually need the most aggressive treatment.
For patients who do not need chemotherapy, that could mean avoiding many of the treatment's difficult side effects without reducing their chances of a good outcome.
Several early clinical trials are exploring treatments that could actually help the body regrow damaged tissue. One approach is focused on regrowing damaged cartilage in the knee. Another, more surprising treatment is designed to stimulate the growth of new teeth.
Researchers are also studying other forms of regenerative medicine. For example, neural stem cells are being investigated as a way to improve recovery after a stroke. Together, these efforts point to a major change in how researchers think about treating damage to the body.
Traditional medicine often manages or replaces what has been lost. That can mean a knee replacement, dentures, or years of physical therapy. Regenerative medicine takes a different approach by trying to help the body rebuild what was damaged. These treatments are still in the early stages and have not been proven on a large scale. But they represent a very different way of thinking about what medical treatment could eventually accomplish.
